ZLDPF Quote, Financials, Valuation and Earnings

Ascendis Pharma AS has a net margin of -3213.72% compared to Zealand Pharma AS's net margin of -93.73%. Zealand Pharma AS's return on equity of -17.27% beat Ascendis Pharma AS's return on equity of -880.05%.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -70.06%. On the other hand Ascendis Pharma AS has an analysts' consensus of $210.33 which suggests that it could grow by 22.24%. Given that Ascendis Pharma AS has higher upside potential than Zealand Pharma AS, analysts believe Ascendis Pharma AS is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.314%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

Zealand Pharma AS quarterly revenues are $1.3M, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. Zealand Pharma AS's net income of -$41.6M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 550.46x versus 25.62x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

Genmab AS has a net margin of -3213.72% compared to Zealand Pharma AS's net margin of 59.7%. Zealand Pharma AS's return on equity of -17.27% beat Genmab AS's return on equity of 23.85%.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -70.06%. On the other hand Genmab AS has an analysts' consensus of $29.50 which suggests that it could grow by 37.34%. Given that Genmab AS has higher upside potential than Zealand Pharma AS, analysts believe Genmab AS is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Genmab AS has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.676%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend.

Zealand Pharma AS quarterly revenues are $1.3M, which are smaller than Genmab AS quarterly revenues of $920.3M. Zealand Pharma AS's net income of -$41.6M is lower than Genmab AS's net income of $549.4M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Genmab AS's PE ratio is 12.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 550.46x versus 4.45x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -3213.72% compared to Zealand Pharma AS's net margin of 32.95%. Zealand Pharma AS's return on equity of -17.27% beat Novo Nordisk AS's return on equity of 86.85%.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -70.06%. On the other hand Novo Nordisk AS has an analysts' consensus of $91.54 which suggests that it could grow by 32.23%. Given that Novo Nordisk AS has higher upside potential than Zealand Pharma AS, analysts believe Novo Nordisk AS is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.33% to investors and pays a quarterly dividend of $1.10 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zealand Pharma AS quarterly revenues are $1.3M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Zealand Pharma AS's net income of -$41.6M is lower than Novo Nordisk AS's net income of $4B. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 21.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 550.46x versus 7.34x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -3213.72% compared to Zealand Pharma AS's net margin of --. Zealand Pharma AS's return on equity of -17.27% beat Viking Therapeutics's return on equity of --.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -70.06%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 207.44%. Given that Viking Therapeutics has higher upside potential than Zealand Pharma AS, analysts believe Viking Therapeutics is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Zealand Pharma AS quarterly revenues are $1.3M, which are larger than Viking Therapeutics quarterly revenues of --. Zealand Pharma AS's net income of -$41.6M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 550.46x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.